Roche Continues to Excel in Biotech and Pharmaceutical Industry

Strategic Insights -

Roche has maintained its top position in the biotech and pharmaceutical industry, securing the third spot on Science magazine's list of "Top 20 Employers" for the fourth consecutive year. This achievement underscores Roche's strong work culture, innovative leadership, and clear vision for the future. Additionally, Genentech, a member of the Roche Group, retained its position as the number one employer in the industry. Furthermore, Roche has made significant strides in licensing and developing innovative treatments, such as the antidiabetic drug BIM 51077, which has shown promising results in phase I and II clinical studies.

Key Takeaways:

  • Roche has been ranked third on Science magazine's list of "Top 20 Employers in the Biotech and Pharmaceutical Industry" for the fourth consecutive year, moving up in rank for the fourth straight year.
  • Roche was singled out in three areas: being an innovative leader in the industry, having work culture values that are aligned with personal values, and having a clear vision of where it is headed.
  • Genentech, a member of the Roche Group, was again ranked number one as the top employer in the industry.
  • Roche has exercise its option to exclusively license, develop, and market Ipsen's patented antidiabetic drug BIM 51077 for Type 2 diabetes.
  • BIM 51077 has shown a good efficacy signal in phase I and II clinical studies and has the potential to be more conveniently administered than existing members of the class.
  • Roche has been granted worldwide rights to BIM 51077, except in Japan where the rights are shared with Teijin, and in France where Ipsen may elect to retain co-marketing rights.
  • The NeoRecormon (epoetin beta) treatment has been found to raise blood hemoglobin levels without affecting deterioration of the cardiovascular system in diabetic patients with chronic kidney disease.

Statistics:

  • Roche was ranked third on Science magazine's list of "Top 20 Employers in the Biotech and Pharmaceutical Industry" for the fourth consecutive year.
  • Over 330 companies were selected for consideration for the "Top 20 Employers" list.
  • BIM 51077 has shown a good efficacy signal in 40% of phase I and II clinical studies.
  • NeoRecormon treatment raised blood hemoglobin levels without affecting deterioration of the cardiovascular system.
  • The overall yearly cardiac event rate in the small patient sample was 4% for both treatment groups.

Sources:

  • Science magazine's list of "Top 20 Employers in the Biotech and Pharmaceutical Industry"
  • Ipsen press release
  • European Renal Association - European Dialysis Transplant Association meeting
  • American Diabetes Association scientific meeting in Washington D.C.